Weight loss “wonder drug” Wegovy will cost Irish users around €220 a month as it is not currently availably under either the ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...

As Robert F. Kennedy Jr. settles into his role as President Donald Trump’s health secretary, one major promise he’s made is ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...

Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment for diabetes and obesity.

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

Semaglutide is the active ingredient in Wegovy It is also the main component of Ozempic Semaglutide is known to increase the risk of hair loss Semaglutide, the main ingredient in Ozempic and ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular weight-loss med at $499 per month. Novo had only launched the cheaper ...

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance, which ...